Stat. Auth.: ORS183, 487.485 & 687.493 Stats. Implemented:ORS183, 687.485 & 687.493 Hist.: Dem 1-2001(Temp), F. & Cert. Ef. 10-1-01 Thru 3-29-02; Dem 1-2002, F. 2-25-02 Cert. Ef. 3-1-02; Dem 6-2010, F. 12-30-10, Cert. Ef. 1-1-11; Ren...

Link to law: http://arcweb.sos.state.or.us/pages/rules/oars_300/oar_332/332_026.html
Published: 2015

The Oregon Administrative Rules contain OARs filed through November 15, 2015

 

QUESTIONS ABOUT THE CONTENT OR MEANING OF THIS AGENCY'S RULES?
CLICK HERE TO ACCESS RULES COORDINATOR CONTACT INFORMATION

 

OREGON HEALTH AUTHORITY

HEALTH LICENSING OFFICE, BOARD OF DIRECT ENTRY MIDWIFERY

 

DIVISION 26
LEGEND
DRUGS AND DEVICES
332-026-0000
Access
to and Administration of Legend Drugs and Devices
(1) An LDM is prohibited from purchasing
or administering legend drugs and devices, including intravenous antibiotics for
Group B Streptococcal prophylaxis until the continuing education listed in OAR 332-020-0010
has been completed and documentation submitted to the office upon renewal in 2016.
(2) Pursuant to ORS 687.493,
an LDM who satisfactorily completes the continuing education OAR 332-020-0010 is
authorized access to and administration of specific legend drugs and devices listed
in OAR 332-026-0010, 332-026-0020, 332-026-0030.
(3) An LDM must comply with
all local, state and federal laws and regulations regarding the administration,
distribution, storage, transportation and disposal of approved legend drugs and
devices listed in OAR 332-026-0010, 332-026-0020, 332-026-0030.
(4) Approved legend drugs
must be inventoried and securely stored by the LDM at all times the product is not
in use, including samples or any remaining portion of a drug.
(5) Records regarding approved
legend drugs and devices must be maintained for a period of three years. Records
must be kept on the business premises and available for inspection upon request
by the Health Licensing Office. Upon request by the board or office, an LDM must
provide a copy of records. Records must include, but are not limited, to the following:
(a) Name of drug, amount
received, date of receipt, and drug expiration date;
(b) Name of drug and to whom
it was administered; date and amount of drug administered to client;
(c) Name of drug, date and
place or means of disposal.
(4) Expired, deteriorated
or unused legend drugs must be disposed of in a manner that protects the licensee,
client and others who may come into contact with the material during disposal.
(5) An LDM is required to
obtain the continuing education for intravenous antibiotics for Group B Streptococcal
prophylaxis, however an LDM is not required to administer the antibiotic.
Stat. Auth.: ORS 676.605, 676.615, 687.485,
687.493
Stats. Implemented: ORS 676.605,
676.615, 687.485, 687.493
Hist.: DEM 1-2001(Temp),
f. & cert. ef. 10-1-01 thru 3-29-02; DEM 1-2002, f. 2-25-02 cert. ef. 3-1-02;
DEM 1-2004, f. 6-29-04, cert. ef. 7-1-04; DEM 6-2010, f. 12-30-10, cert. ef. 1-1-11;
Renumbered from 332-025-0030 by DEM 5-2011, f. & cert. ef. 9-26-11; DEM 2-2015,
f. & cert. ef. 7-1-15
332-026-0010
Approved
Legend Drugs For Maternal Use
Licensees may administer the following
legend drugs as approved by the board for maternal use:
(1) Anti-Hemorrhagics for
use by intramuscular injection includes:
(a) Synthetic Oxytocin (Pitocin,
Syntocin and generic);
(b) Methylergonovine (Methergine);
(c) Ergonovine (Ergotrate);
or
(2) Anti-Hemorrhagics by
intravenous infusion is limited to Synthetic Oxytocin (Pitocin, Syntocin, and generic).
(3) Anti-Hemorrhagics for
oral administration is limited to:
(a) Methylergonovine (Methergine);
(b) Misoprostol (Cytotec).
(4) Anti-Hemorrhagics for
rectal administration is limited to Misoprostol (Cytotec).
(5) Resuscitation is limited
to medical oxygen and intravenous fluid replacement.
(6) Intravenous fluid replacement
includes:
(a) Lactated Ringers Solution;
(b) 0.9% Saline Solution;
(c) D5LR (5% Dextrose in
Lactated Ringers); or
(d) D5W (5% Dextrose in water).
(7) Anaphylactic treatment
by subcutaneous injection is limited to Epinephrine.
(8) Local anesthetic includes:
(a) Lidocaine HCl (1% and
2%) (Xylocaine and generic);
(b) Topical anesthetic;
(c) Procaine HCl (Novocain,
benzocaine, cetacane and generic); and
(d) Sterile water papules.
(9) Rhesus Sensitivity Prophylaxis
is limited to Rho(d) Immune Globulin (RhoGAM, Gamulin Rh, Bay Rho-D and others).
(10) Tissue adhesive (Dermabond
or generic).
(11) Intravenous antibiotics
for Group B Streptococcal prophylaxis is limited to the following and is only to
be used solely for the purpose of Group B Streptococcal prophylaxis:
(a) Penicillin;
(b) Ampicillin;
(c) Cefazolin; or
(d) Clindamycin.
Stat. Auth.: ORS 676.605,
676.615, 687.485 & 687.493
Stats. Implemented: ORS 676.605, 676.615,
687.485 & 687.493
Hist.: DEM 1-2001(Temp),
f. & cert. ef. 10-1-01 thru 3-29-02; DEM 1-2002, f. 2-25-02 cert. ef. 3-1-02;
DEM 1-2004, f. 6-29-04, cert. ef. 7-1-04; DEM 6-2010, f. 12-30-10, cert. ef. 1-1-11;
DEM 1-2011(Temp), f. & cert. ef. 4-4-11 thru 9-27-11; Renumbered from 332-025-0040
by DEM 5-2011, f. & cert. ef. 9-26-11; DEM 2-2015, f. & cert. ef. 7-1-15
332-026-0020
Approved
Legend Drugs For Neonatal Use
Licensees may
administer the following legend drugs as approved by the board for neonatal use:
(1) Eye
Prophylaxis for disease of the newborn is limited to Erythromycin Ophthalmic (0.5%)
Ointment (Ilotycin, AK-Mycin and generics).
(2) Prophylaxis
for hemorrhagic disease of the newborn for oral use is limited to Mephyton.
(3) Prophylaxis
for hemorrhagic disease of the newborn for intramuscular injection includes:
(a) AquaMephyton;
and
(b) Konakion.
(4) Resuscitation
is limited to medical oxygen.
Stat. Auth.:
ORS 676.605, 676.615, 687.485 & 687.493

Stats.
Implemented: ORS 676.605, 676.615, 687.485 & 687.493

Hist.:
DEM 1-2001(Temp), f. & cert. ef. 10-1-01 thru 3-29-02; DEM 1-2002, f. 2-25-02
cert. ef. 3-1-02; DEM 1-2004, f. 6-29-04, cert. ef. 7-1-04; DEM 6-2010, f. 12-30-10,
cert. ef. 1-1-11; Renumbered from 332-025-0050 by DEM 5-2011, f. & cert. ef.
9-26-11
332-026-0030
Approved
Devices
Licensees may
use or provide as appropriate the following devices as approved by the board:
(1) Devices
for injection of medications including:
(a) Needles;
and
(b) Syringes.
(2) Devices
for administration of intravenous fluids including:
(a) Drip
sets; and
(b) Catheters.
(3) Devices
for maternal and neonatal resuscitation including:
(a) Suction
devices;
(b) Oxygen-delivery
devices; and
(c) Bag-Valve-Mask-Sets.
(4) Devices
for rupturing the amniotic sac.
(5) Devices
for repairing the perineal area including:
(a) Sutures;
(b) Instruments
for completing a repair; and
(c) Local
anesthetic administration devices.
(6) Barrier
methods of contraception.
Stat. Auth.:
ORS 183, 487.485 & 687.493

Stats.
Implemented: ORS 183, 687.485 & 687.493

Hist.:
DEM 1-2001(Temp), f. & cert. ef. 10-1-01 thru 3-29-02; DEM 1-2002, f. 2-25-02
cert. ef. 3-1-02; DEM 6-2010, f. 12-30-10, cert. ef. 1-1-11; Renumbered from 332-025-0060
by DEM 5-2011, f. & cert. ef. 9-26-11


The official copy of an Oregon Administrative Rule is
contained in the Administrative Order filed at the Archives Division,
800 Summer St. NE, Salem, Oregon 97310. Any discrepancies with the
published version are satisfied in favor of the Administrative Order.
The Oregon Administrative Rules and the Oregon Bulletin are
copyrighted by the Oregon Secretary of State. Terms
and Conditions of Use
Read Entire Law on arcweb.sos.state.or.us